[Retinal vein occlusions: diseases for the internist?]

D Prisco1, L Bertini, R Marcucci

  • 1Centro di Riferimento Regionale per la Trombosi, Università degli Studi, Azienda Ospedaliera Careggi di Firenze. d.prisco@dfc.unifi.it

Annali Italiani Di Medicina Interna : Organo Ufficiale Della Societa Italiana Di Medicina Interna
|June 8, 2000
PubMed

Insights

Central retinal vein occlusion, a common condition linked to internal medicine issues, is significantly associated with elevated levels of plasminogen activator inhibitor-1 (PAI-1), lipoprotein(a), and hyperhomocysteinemia, offering new insights into its pathogenesis.

Area of Science:

  • Ophthalmology
  • Internal Medicine
  • Hematology

Context:

  • Retinal vein occlusion (RVO) is a prevalent vascular disorder.
  • Central retinal vein occlusion (CRVO) is the most common and impactful form.
  • CRVO is frequently associated with systemic internal medicine conditions.

Purpose:

  • To investigate novel hemostasis-related risk factors in CRVO pathogenesis.
  • To evaluate the role of specific biomarkers in CRVO development.
  • To explore potential prognostic and therapeutic implications of these findings.

Summary:

  • While classic risk factors for CRVO are established, emerging research highlights hemostasis-related factors.
  • High levels of type 1 plasminogen activator inhibitor (PAI-1), lipoprotein(a), and hyperhomocysteinemia are implicated in CRVO pathogenesis.
  • Data on some parameters remain contradictory, necessitating further investigation.

Impact:

  • Identifies key hemostasis markers (PAI-1, lipoprotein(a), hyperhomocysteinemia) contributing to CRVO.
  • Suggests potential for improved prognostic assessment in CRVO patients.
  • Opens avenues for novel therapeutic strategies targeting these specific pathways.